Analyst Price Targets — ASMB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 1, 2026 11:41 am | Salim Syed | Mizuho Securities | $53.00 | $33.63 | TheFly | Assembly Biosciences price target raised to $53 from $45 at Mizuho |
| September 1, 2026 8:08 am | Ashwani Verma | UBS | $52.00 | $33.63 | StreetInsider | UBS Starts Assembly Biosciences (ASMB) at Buy |
| August 18, 2026 10:41 am | Patrick Trucchio | H.C. Wainwright | $50.00 | $30.01 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Assembly Biosciences (ASMB) |
| June 15, 2026 10:57 am | — | Mizuho Securities | $45.00 | $22.96 | TheFly | Assembly Biosciences price target raised to $45 from $40 at Mizuho |
| November 20, 2025 12:09 pm | Salim Syed | Mizuho Securities | $40.00 | $39.00 | TheFly | Assembly Biosciences price target raised to $40 from $29 at Mizuho |
| September 24, 2025 8:29 am | Roy Buchanan | JMP Securities | $38.00 | $25.90 | TheFly | Assembly Biosciences initiated with an Outperform at Citizens JMP |
| September 24, 2024 6:41 am | Salim Syed | Mizuho Securities | $36.00 | $16.26 | StreetInsider | Mizuho Reiterates Outperform Rating on Assembly Biosciences (ASMB) |
| September 20, 2024 3:30 am | Dennis Ding | Jefferies | $35.00 | $18.50 | StreetInsider | Jefferies Upgrades Assembly Biosciences (ASMB) to Buy |
Latest News for ASMB
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present during the H.C. Wainwright & Co. 28th Annual Global Investment Conference at 8:30 a.m. Eastern Time on September 16, 2026.
COCO, CHEF, ASMB and CDNA stand out as four defensive picks amid volatility induced by rising oil prices and Middle East tensions.
– Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes –
The average of price targets set by Wall Street analysts indicates a potential upside of 35.7% in Assembly Biosciences (ASMB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Assembly Biosciences, Inc. (ASMB) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ASMB's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ASMB.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.